BidaskClub lowered shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a strong-buy rating to a buy rating in a research report released on Saturday.
Several other brokerages also recently weighed in on VNDA. Oppenheimer set a $27.00 price objective on Vanda Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, February 15th. ValuEngine raised Vanda Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, December 20th. Jefferies Group reaffirmed a buy rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a report on Tuesday, February 13th. Finally, Seaport Global Securities began coverage on Vanda Pharmaceuticals in a report on Friday, January 19th. They issued a buy rating and a $20.00 target price for the company. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Vanda Pharmaceuticals presently has an average rating of Buy and a consensus price target of $21.57.
Shares of Vanda Pharmaceuticals (VNDA) opened at $16.90 on Friday. Vanda Pharmaceuticals has a 1 year low of $11.90 and a 1 year high of $20.40. The firm has a market capitalization of $837.27, a price-to-earnings ratio of -49.70 and a beta of 1.02.
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.08. Vanda Pharmaceuticals had a negative return on equity of 11.94% and a negative net margin of 9.43%. The business had revenue of $44.28 million during the quarter, compared to the consensus estimate of $44.00 million. During the same period in the prior year, the company earned $0.08 EPS. Vanda Pharmaceuticals’s revenue for the quarter was up 15.8% on a year-over-year basis. equities analysts forecast that Vanda Pharmaceuticals will post -0.13 EPS for the current year.
In other Vanda Pharmaceuticals news, CFO James Patrick Kelly sold 8,532 shares of the company’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $18.72, for a total value of $159,719.04. Following the completion of the transaction, the chief financial officer now owns 208,066 shares of the company’s stock, valued at approximately $3,894,995.52. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Gunther Birznieks sold 8,568 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $15.26, for a total value of $130,747.68. Following the completion of the transaction, the senior vice president now directly owns 118,366 shares of the company’s stock, valued at approximately $1,806,265.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 287,506 shares of company stock valued at $4,665,795. Insiders own 7.60% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its stake in shares of Vanda Pharmaceuticals by 2.4% in the fourth quarter. BlackRock Inc. now owns 4,568,159 shares of the biopharmaceutical company’s stock valued at $69,436,000 after buying an additional 106,228 shares during the period. Armistice Capital LLC increased its stake in shares of Vanda Pharmaceuticals by 74.8% in the fourth quarter. Armistice Capital LLC now owns 2,678,000 shares of the biopharmaceutical company’s stock valued at $40,706,000 after buying an additional 1,146,000 shares during the period. Macquarie Group Ltd. increased its stake in shares of Vanda Pharmaceuticals by 20.0% in the fourth quarter. Macquarie Group Ltd. now owns 2,268,691 shares of the biopharmaceutical company’s stock valued at $34,484,000 after buying an additional 378,606 shares during the period. Renaissance Technologies LLC increased its stake in shares of Vanda Pharmaceuticals by 17.8% in the fourth quarter. Renaissance Technologies LLC now owns 1,434,850 shares of the biopharmaceutical company’s stock valued at $21,810,000 after buying an additional 216,600 shares during the period. Finally, Rothschild Asset Management Inc. acquired a new stake in shares of Vanda Pharmaceuticals in the third quarter valued at about $23,491,000. 89.96% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This report was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/03/21/vanda-pharmaceuticals-vnda-stock-rating-lowered-by-bidaskclub.html.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.